Infliximab appears efficacious for patients with juvenile-onset spondyloarthritis who have failed to respond to conventional treatment, phase 3 study findings show.

CT-P13 SC is the first SC formulation of infliximab that received regulatory approval and may be termed a biobetter as it offers significant clinical advantages over intravenous (IV) infliximab, including improved pharmacokinetics and a convenient mode of delivery.

medwireNews : The EMA’s Committee for Medicinal Products for Human Use has expanded the indication of subcutaneous infliximab to include psoriatic arthritis (PsA) and ankylosing spondylitis (AS).

The decision to discontinue infliximab in ankylosing spondylitis patients who have achieved sustained remission “should be taken with considerable caution,” say Spanish researchers who found that over half relapsed after the tumor necrosis factor inhibitor was withdrawn.

The clinical benefit of infliximab dose escalation in people with rheumatoid arthritis may be limited to the initial two escalations, US study findings indicate.

Using infliximab-dyyb instead of the reference product may not reduce out-of-pocket costs for US rheumatoid arthritis patients insured on the Medicare Part D system, study results suggest.

Using infliximab-dyyb instead of the reference product may not reduce out-of-pocket costs for US rheumatoid arthritis patients insured on the Medicare Part D system, study results suggest.